LiStarFish - DIAGNOSTICA / RICERCA, CITOGENETICA - Prodotti per la ricerca medica

Categorie
Video
Focus On
Social Network
ELISA e LC-MS/MS per i Farmaci Biologici, gli anticorpi antifarmaco e gli auto-anticorpi HAHA e HAMA

TNF alpha (Infliximab, Remsima, Golimumab, Adalimumab, Etanercept), EGFR (Cetuximab-Erbitux), VEGF (Bevacizumab), CD20 (Rituximab), HER2 (Trastuzumab), Vedolizumab (Entyvio), Denosumab (Prolia®), Omalizumab (Xolair®), Tocilizumab (Actemra®), Nivolumab (Opdivo®), Pembrolizumab (Keytruda®), Ipilimumab (Yervoy®), Filgrastim (Accofil®, Granulokine®, Nivestim®) e anti HAHA e anti HAMA.

Li StarFish propone una serie di kit per l'applicazione e il dosaggio dei farmaci biologici utilizzati principalmente nella cura delle patologie reumatologiche, psoriasi, patologie infiammatorie e gastrointestinali (morbo di Crohn) ed in oncologia.

Inoltre questi test permettono di valutare gli anticorpi preesistenti o indotti dall'utilizzo dei farmaci biologici in terapia che possono alterare l'efficacia terapeutica.

 
LISTA PRODOTTI >>Clicca qui
 
TNFa e TNFa blocker
Determinazione quantitativa dei TNF blocker, Anti-TNF blocker (Infliximab, Remsima, Golimumab-Simponi®, Adalimumab-Humira®, Etanercept-Enbrel®), Human TNFa e TNF receptor II
     
1-s2.0-s0049017205000065-gr1.jpg
       
 REMSIMA:      

MAT-TR-REMSv1 SHIKARI Q-REMS Enzyme immunoassay for the quantitative determination of free Infliximab (Remsima®) in serum and plasma CE/IVD.

MAT-TR-AREMSv2 SHIKARI S-AIR Enzyme immunoassay for the quantitative determination of antibodies to Infliximab Remsima in serum and plasma CE/IVD.

 
 GOLIMUMAB-SIMPONI:

MAT-TR-GOLv2  SHIKARI Q-GOL Enzyme immunoassay for the quantitative determination of free Golimumab (Simponi®) in serum and plasmA CE/IVD.

MAT-TR-ATGv1  SHIKARI S-ATG Enzyme immunoassay for the qualitative determination of antibodies to Golimumab in serum and plasma CE/IVD.

 
 INFLIXIMAB:

MAT-TR-Q-INFLIXIv2 SHIKARI Q-INFLIXI Enzyme immunoassay for the quantitative determination of free Infliximab (Remicade®) in serum and plasma CE/IVD.

MAT-TR-ATIv6 SHIKARI Q-ATI Enzyme immunoassay for the quantitative determination of specific antibodies to infliximab in human serum and plasma CE/IVD.

DRG-EIA5680 TNFa blocker ADA, TOTAL ANTIBODIES AGAINST INFLIXIMAB (Remicade®)
 
 ADALIMUMAB:

MAT-TR-ADAv1  SHIKARI Q-ADA Enzyme immunoassay for the quantitative determination of free adalimumab (Humira®) in serum and plasma CE/IVD.

MAT-TR-A-ADAv2 SHIKARI S-ATA Enzyme immunoassay for the quantitative determination of antibodies to adalimumab in serum and plasma CE/IVD.

DRG-EIA56-- TNFa blocker ADA, TOTAL ANTIBODIES AGAINST ADALIMUMAB (Humira®).
 
 ETANERCEPT:

MAT-TR-ETAv2 SHIKARI Q-ETA Enzyme immunoassay for the quantitative determination of free Etanercept (Enbrel®) in serum and plasma.

MAT-TR-AETAv2 SHIKARI S-ATE Enzyme immunoassay for the qualitative determination of antibodies to etanercept in serum and plasma.

 
EGFR Cetuximab
cetuximab.jpg    
Determinazione quantitativa di EGFR blocker e degli anti-EGFR blocker (Cetuximab)
       
 EGFR Cetuximab:      

MAT-TR-CETv1 SHIKARI Q-CET Enzyme immunoassay for the quantitative determination of free Cetuximab (Erbitux®) in serum and plasma.

MAT-TR-ACETv1 SHIKARI S-ATC Enzyme immunoassay for the qualitative determination of antibodies to cetuximab in serum and plasma.

       
 VEGF e VEGF blocker
Determinazione quantitativa dei VEGF blocker e degli anti-VEGF blocker (Bevacizumab).

Farmaci che agiscono inibendo l’angiogenesi,  ostacolano lo sviluppo dei vasi sanguigni che irrorano i tumori.

     
bevacizumab.jpg
       
 BEVACIZUMAB:      

MAT-TR-BEVAv2 SHIKARI Q-BEVA Enzyme immunoassay for the quantitative determination of Bevacizumab (Avastin®) in serum and plasma.

MAT-TR-ABEVAv2 SHIKARI S-ATB Enzyme immunoassay for the quantitative determination of antibodies to Bevacizumab (Avastin®) in serum and plasma.
       
 CD20 e anti-CD20
rituximab.jpg
   

Determinazione qualitativa di anti-CD20 (Rituximab)

MabThera - rituximab
 
Il rituximab viene
MabThera - rituximab
 
usato  per curare il linfoma non Hodgkin, la leucemia linfocitica cronica e l'artrite reumatoide.

       
 RITUXIMAB:       
MAT-TR-RTXv2 SHIKARI Q-RITUX Enzyme immunoassay for the quantitative determination of Rituximab® (Rituxan®, Mabthera®) in serum and plasma CE/IVD
MAT-TR-ARTXv2 SHIKARI S-ATR Enzyme immunoassay for the quantitative determination of antibodies to Rituximab (Rituxan®, Mabthera®) in serum and plasma 
       

 

 HER2 e anti-HER2
trastuzumab.jpeg
   

Determinazione quantitativa di HER2 (Trastuzumab).

Il Trastuzumab, nome commerciale Herceptin, è un anticorpo monoclonale umanizzato utilizzato per contrastare il carcinoma mammario avanzato, recidivante o diffuso ad altri organi (carcinoma mammario secondario).

       
  TRASTUZUMAB:      

MAT-TR-TRASv1 SHIKARI Q-TRAS Enzyme immunoassay for the quantitative determination of Trastuzumab (Herceptin®, Herclon®).

MAT-TR-ATRASV2 SHIKARI S-ATT Enzyme immunoassay for the qualitative determination of antibodies to Trastuzumab (Herceptin®, Herclon®) in serum and plasma CE/IVD

 

VEDOLIZUMAB
 

Determinazione di  VEDOLIZUMAB.

Il VEDOLIZUMAB, nome commerciale Entyvio, è impiegato per il trattamento, negli adulti, del Morbo di Crohn (moderato-severo) e della Colite Ulcerosa.

     francescoquatraro_vzm-02b.jpg
 VEDOLIZUMAB:
IMM-KM9600 Vedolizumab drug level LC-MS/MS Kit for the in vitro determination of free vedolizumab
concentration (e. g. Entyvio®) in EDTA plasma and serum.
 
 DENOSUMAB
 f1.large.jpg    

Denosumab (PROLIA®) è un anticorpo monoclonale IgG2 umanizzato con affinità e specificità per RANKL. Inibisce RANKL dall'attivare il suo recettore, diminuendo in tal modo il riassorbimento osseo. Denosumab ha un peso molecolare di circa 147 kDa ed è prodotto in cellule geneticamente modificate di mammifero.

Applicazione nel trattamento dell'osteoporosi.

 DENOSUMAB:

MAT-TR-DENv1 SHIKARI Q-DEN Enzyme immunoassay for the quantitative determination of denosumab (Prolia®) in serum and plasma CE/IVD.

MAT-TR-ATD SHIKARI S-ATD Enzyme immunoassay for the qualitative determination of antibodies to Denosumab in serum and plasma CE/IVD.

 
OMALIZUMAB
Omalizumab (Xolair®) è un anticorpo monoclonale IgG1κ umanizzato da DNA ricombinante che si lega selettivamente alle immunoglobuline E (IgE) umane. Farmaco a prescrizione, iniettabile, usato per il trattamento in adulti, bambini sopra i 12 anni di età e anziani con moderata a grave asma persistente i cui sintomi dell'asma non sono controllati da corticosteroidi per via inalatoria.      nrd1224-f8.jpg
 OMALIZUMAB:

MAT-TR-OMAv1 SHIKARI Q-OMA Enzyme immunoassay for the quantitative determination of omalizumab (Xolair®)  in serum and plasma CE/IVD.

MAT-TR-ATOv1 SHIKARI S-ATO Enzyme immunoassay for the qualitative determination of antibodies to Omalizumab in serum and plasma CE/IVD

 
TOCILIZUMAB
texte_alt_jlejpc0247gr2.jpg     Tocilizumab (Actemra®) è un anticorpo monoclonale umanizzato, è un farmaco immunosoppressore , studiato principalmente per il trattamento dell'artrite reumatoide (AR) e dell'artrite idiopatica giovanile sistemica, una grave forma di artrite reumatoide dei bambini.

Il farmaco è attivo contro il recettore dell'interleuchina-6 (IL-6R). L'interleuchina-6 (IL-6) è una citochina che gioca un ruolo importante nella risposta immunitaria ed è implicata nella patogenesi di molte malattie, quali le malattie autoimmuni, il mieloma multiplo e il cancro della prostata.
 TOCILIZUMAB:

IG-AB108 Enzyme immunoassay for the specific and quantitative determination of free Tocilizumab (Actemra®) in human serum and plasma CE/IVD.

IG-BB108 Enzyme immunoassay for the semi-quantitative determination of free antibodies to Tocilizumab (Actemra®) in human serum and plasma CE/IVD

 
 NIVOLUMAB

Nivolumab (Opdivo®) è un anticorpo monoclonale anti-PD-1 che attiva il sistema immunitario agendo sulle cellule-T, le quali intervengono con una risposta immune contro le cellule tumorali.

Approvato per il trattamento del tumore del polmone, del tumore del rene e del Linfoma di Hodgkin.

 

     oprivo-ii.png
 NIVOLUMAB:

MAT-TR-Q-NIVOv1 SHIKARI Q-NIVO Enzyme immunoassay for the quantitative determination of nivolumab (Opdivo®) in serum and plasma CE/IVD

MAT-TR-ATNv1 SHIKARI S-ATN Enzyme immunoassay for the qualitative determination of antibodies to nivolumab (Opdivo®) in serum and plasma CE/IVD

 
 PEMBROLIZUMAB
immune-checkpoint-enlarge.__v100154616.jpg    

Pembrolizumab (Keytruda®) è un anticorpo monoclonale anti-PD-1, che attiva il sistema immunitario stimolando la proliferazione delle cellule T, le quali montano una risposta immune più attiva contro le cellule tumorali.

Come funziona: blocca l’interazione tra il recettore PD-1 ed il suo ligando PD-L1, che regola in condizioni normali le cellule T del sistema immunitario. Bloccando tale legame permette alle cellule T di attivarsi e proliferare, così da attaccare le cellule tumorali.

Pembrolizumab è approvato per pazienti con melanoma in stadio III non operabile o in stadio IV, indipendentemente dalla presenza della mutazione di BRAF. 

 

 PEMBROLIZUMAB:

MAT-TR-PEMv1 SHIKARI Q-PEM Enzyme immunoassay for the quantitative determination of Pembrolizumab (Keytruda®) in serum and plasma

MAT-TR-A-PEMv1 SHIKARI S-ATP Enzyme immunoassay for the qualitative determination (screening) of antibodies to Pembrolizumab (Keytruda®) in serum and plasma

 
IPILIMUMAB

Ipilimumab è un anticorpo monoclonale anti-CTLA-4, che attiva il sistema immunitario stimolando la proliferazione delle cellule-T, le quali sviluppano una risposta immune più attiva contro le cellule tumorali.

Ipilimumab è approvato per pazienti con melanoma in stadio III non operabile o in stadio IV.

 

 

     figure-1-final.jpg
 IPILIMUMAB:

MAT-TR-IPIv1 SHIKARI Q-IPI Enzyme immunoassay for the quantitative determination of specific Ipilimumab(Yervoy®) in human serum and plasma

MAT-TR-AIPIv1 SHIKARI S-ATI Enzyme immunoassay for the qualitative determination of specific antibodies to Ipilimumab(Yervoy®) in human serum and plasma

 
 FILGRASTIM
 index.png      Filgrastim si utilizza per:
  • ridurre la durata della neutropenia (basso numero di globuli bianchi) in corso di terapie con farmaci citotossici o mielotosssici. Questo consente di ridurre il rischio di infezioni concomitanti dovuti alla carenza neutropenica, in pazienti che stanno seguendo un trattamento terapeutico antitumorale citotossico
  • preparazione al trapianto di midollo osseo
  • neutropenia cronica grave
  • neutropenia in pazienti con infezione da HIV
  • mobilizzazione cellule staminali dal sangue periferico
 FILGRASTIM:
MAT-TR-AFAv1 SHIKARI Q-AFA Enzyme immunoassay for the quantitative determination of specific antibodies to Filgrastim in human serum and plasma with confirmation reagent (for 20 samples)
 
 HAMA e HAHA
 

Questi test  permettono di rivelare la presenza di auto anticorpi HAMA, HAHA e MAHA  che possono influenzare la diagnosi e il trattamento con farmaci biologici nei pazienti.

 

   

EPI-KT806 HAHA (Human Anti-human Antibody) ELISA Kit, CE IVD

EPI-KT805 HAMA (Human Anti- Mouse Antibody) ELISA Kit, CE IVD

EPI-KT807 MAHA (Mouse Anti-human Antibody) ELISA Kit

       
Letteratura:
1
Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, Volume 4, Article 1, 2017.**
Gregoritza M, Messmann V, Abstiens K, Brandl FP, Göpferich AM, Controlled antibody release from degradable thermoresponsive hydrogels cross-linked by Diels-Alder chemistry, Biomacromolecules, Just Accepted Manuscript, 22 Jun 2017.
Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017.**
Kolar M, Duricova D, Bortlik M, et al., Infliximab Biosimilar (Remsima TM ) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre, Digestive Disease, 35:91–100, 2017.
Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.**
Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL,Bibby BM, Uldbjerg N, Connell WR, Rosella O, Grosen A, Brown SJ, Kjeldsen J,Wildt S, Svenningsen L, Sparrow MP, Walsh A, Connor SJ, Radford-Smith G, LawranceIC, Andrews JM, Ellard K, Bell SJ. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology. Jul;151(1):110-9, 2016.**
Jonathan GG, Beatriz AÁ, Nazco C GJ, Norberto BL, Fernando GN. Plasma levels of trastuzumab in gastric cancer: Case report. J Oncol Pharm Pract. Sep 23, 2016.**
Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.**
Chen L., et al., Efficient Production of a Bioactive Bevacizumab Monoclonal Antibody Using the 2A Self-cleavage Peptide in Transgenic Rice Callus. Frontiers in Plant Science August 2016 | Volume 7 | Article 1156.**
10  Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published April 21, 2016.
11  Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol. Apr;111(4):529-40, 2016.
12  Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**
13  Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155–166 **
14  Bortlik M., et al., Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol. 51, no. 2, 196–202.
15  Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.**
16  Kui R, Gál B, Gaál M, Kiss M, Kemény L1, Gyulai R. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol. Sep;43(9):1018-23, 2016.**
17  Bodini G., Edoardo G. Giannini, Edoardo V. Savarino, and Vincenzo Savarino. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Infl ammatory Bowel Disease: A Useful Cutoff in Clinical Practice. Am J Gastroenterol. Vol. 110, March, 2015.
18  Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol (2015) 50:758–768.
19  Fujita T, Murata Y, Hemmi S, Kajiwara M, Yabuki M, et al. (2015) Persistent Complement Activation is Associated with Insulin Resistance and Chronic Inflammation in Overweight Patients with Type 2 Diabetes with Dyslipidemia. Int J Immunol Immunother 2:007, 2015. **
20  Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015.
21  Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis experiences from a single center. Expert Opin. Biol. Ther. 15:(9) 2015.
22  Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to ‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737–743), 2015.
23  Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.**
24  Bergen T.V., et al., Complementary effects of bevacizumab and MMC in the improvement of surgical outcome after glaucoma filtration surgery. Acta Ophthalmologica 2015, 667-678.**
25  Aydın C, Ataoğlu H., Demonstration of β-1,2 Mannan Structures Expressed on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal Form by Using Monoclonal Antibodies Mikrobiyol Bul 49(1): 66-76, 2015.
26  Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. **
27  Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **
28  Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology& Hepatology 26:(485-487), 2014.
29  Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014. **
30  Avdeeva A.A., Aleksandrova E.N., Karateev D.E., Luchikhina E.L., Novikov A.A., Cherkasova M.V., Nasonov E.L. EFFICACY OF ADALIMUMAB IN EARLY RHEUMATOID ARTHRITIS IN RELATION TO ITS SERUM LEVEL AND THE PRESENCE OF ANTI-DRUG ANTIBODY. Rheumatology Science and Practice. 52(6):624–630. 2014 Russian, English abstract
http://rsp.ima-press.net/rsp/article/view/2007
31  Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.
32  Jung Y et al., “Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis”, J. Control. Release 2013.
33  Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **
34  Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. **
35  Romero G., et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF-α. Macromol. Biosci. 13: (903–912), 2013.
36  Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages **http://dx.doi.org/10.1155/2013/620837
37  Bortlik M et al, “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study”, Scandinavian Journal of Gastroenterology. 48: 951–958, 2013
38  Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis 2012. **
39  Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. **
40  Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **
41  Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249 **
42  Molnar T, et al, “Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease”, Z Gastroenterol 2012; 50 - A53
43  Kato S, et al, “Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient”, Crohn’s & Colitis Foundation of America 2011
44  Adisen E, et al, “Anti-infliximab antibody status and its relation to clinical response in psoriatic patients”: A pilot study, Journal of Dermatology 2010; 37: 708–713.
 Poster:
1
Malickova K, et al,. Monitoring patients treated with infliximab: Assessing Anti-Infliximab antibodies, Czech Republic. EUROMEDLAB. Autoimmune diseases 2009. S115
Malickova K, et al, Formation of antiphospholipid antibodies and antibodies to infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases, Charles University in Prague Czech Republic (2011).
Malickova K, et al, Relationship between serum trough infliximab levels, serum antibodies to infliximab, serum albumin levels and clinical response to infliximab treatment in patients with inflammatory bowel diseases, Charles University in Prague Czech Republic. (2011)
Lukas M, et al, Anti-infliximab antibodies in routine clinical practice is it worth to assess them, Czech Republic
Duricova D, et al, Predictors of sustained response to infliximab with Crohn’s disease: A single cohort study, Czech Republic
Bodini G, et al, Correlation between Adalimumab trough serum concentration, Anti-Adalimumab antibodies and TNF-Alpha levels with clinical outcome in patients affected by Crohn’s disease,. United European Gastroenterology. Italy 2013.
Julsgaard M, et al, Time since last drug exposure in pregnancy determines Adalimumab and Infliximab levels in neonates(Era Study), Italy 2014
Szepes Z., et al, Clinical utility of measuring serum TNF alpha level, anti TNF alpha levels and antibody titers in critical situations in inflammatory bowel disease and in psoriasis, ECCO 2014 Inflammatory Bowel Disease.
Julsgaard M., et al, Intra-uterine Exposure to Anti-TNF-alpha therapy(ERA study):Infliximab and adalimumab cord blood levels correlate with maternal levels at birth, ECCO 2014 Inflammatory Bowel Disease.
10  Goldberg R., et al, Predictors of sub-therapeutic infliximab oradalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions, ECCO 2014 Inflammatory Bowel Disease.
11  H. Akbulut, et al: The role of immune system on the efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC). Medical Oncology, Ankara University School of Medicine, Ankara, Turkey. 1553 P, Annals of Oncology, Volume 27, 2016, 7–11 October 2016, Copenhagen, Denmark.

 Per ulteriori informazioni CONTATTACI

design & hosting by Playground Web Agency Milano
0.2 seconds to elaborate this page.